PAX8 Antibody

說明書

中文名稱：

PAX8兔多克隆抗體
貨號(hào)：

CSB-PA919764
規(guī)格：

￥1100
圖片：
The image on the left is immunohistochemistry of paraffin-embedded Human thyroid cancer tissue using CSB-PA919764(PAX8 Antibody) at dilution 1/35, on the right is treated with fusion protein. (Original magnification: ×200)

Gel: 10%SDS-PAGE, Lysate: 40 μg, Lane 1-2: MCF7 cells, mouse brain tissue, Primary antibody: CSB-PA919764(PAX8 Antibody) at dilution 1/250, Secondary antibody: Goat anti rabbit IgG at 1/8000 dilution, Exposure time: 2 minutes
其他：

產(chǎn)品詳情
產(chǎn)品評(píng)價(jià)
相關(guān)產(chǎn)品
靶點(diǎn)詳情

產(chǎn)品詳情

Uniprot No.：

Q06710
基因名：

PAX8
別名：

OTTHUMP00000158659 antibody; OTTHUMP00000158660 antibody; OTTHUMP00000203723 antibody; OTTHUMP00000203724 antibody; Paired box 8 antibody; Paired box gene 8 antibody; paired box homeotic gene 8 antibody; Paired box protein Pax 8 antibody; Paired box protein Pax-8 antibody; Paired domain gene 8 antibody; PAX 8 antibody; PAX8 antibody; PAX8_HUMAN antibody
宿主：

Rabbit
反應(yīng)種屬：

Human,Mouse,Rat
免疫原：

Fusion protein of Human PAX8
免疫原種屬：

Homo sapiens (Human)
標(biāo)記方式：

Non-conjugated
抗體亞型：

IgG
純化方式：

Antigen affinity purification
濃度：

It differs from different batches. Please contact us to confirm it.
保存緩沖液：

-20°C, pH7.4 PBS, 0.05% NaN3, 40% Glycerol
產(chǎn)品提供形式：

Liquid
應(yīng)用范圍：

ELISA,WB,IHC

推薦稀釋比：

Application	Recommended Dilution
ELISA	1:1000-1:2000
WB	1:200-1:1000
IHC	1:15-1:50

Protocols：

ELISA Protocol
Western Blotting (WB) Protocol
Immunohistochemistry (IHC) Protocol
儲(chǔ)存條件：

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
貨期：

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
用途：

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

產(chǎn)品評(píng)價(jià)

靶點(diǎn)詳情

功能：

Transcription factor for the thyroid-specific expression of the genes exclusively expressed in the thyroid cell type, maintaining the functional differentiation of such cells.
基因功能參考文獻(xiàn)：
1. PAX8-PPARG fusions may not play major roles in the tumorigenesis of paediatric follicular thyroid carcinoma. PMID: 28621837
2. Identify several novel PAX8 mutations in congenital hypothyroidism patients that impair the binding or activating abilities of PAX8 at the promoters of the target genes thyroglobulin and thyroperoxidase. PMID: 28060725
3. Data suggest that candidate genes and pathways regulated by PAX8 that could be additional targets for the therapy of ovarian carcinoma. PMID: 27259239
4. PAX8 has a cell specific role in governing proliferation and migration in nontransformed ovarian surface epithelium cells compared to the oviductal cells, but its reduction in serous cancer cell lines provides a common mechanism for reducing cell survival. PMID: 27129161
5. findings proved that iodinated TG in thyroid follicular lumen regulated TTF-1 and PAX8 expression through thyroid stimulating hormone/thyroid stimulating hormone receptor (TSH/TSHR) mediated cAMP-PKA and PLC-PKC signaling pathways. PMID: 28322461
6. Case Report: primary seminal vesicle carcinoma strong and diffuse nuclear labeling for PAX8. PMID: 28506732
7. PAX8 is expressed in both benign and malignant mesothelium, and that BAP1 loss is highly specific for malignant peritoneal neoplasms, in the differential with both benign mesothelial proliferations and ovarian serous tumors. PMID: 28877056
8. Although the exact biological function remains to be explored, our findings suggest a possible association of PAX8eQTLs in lncRNA AC016683.6 with the hepatocellular carcinoma prognosis in the Chinese population. PMID: 28339471
9. findings point to significant PTC-associated dysregulation of several PAX8 target genes, supporting the notion that PAX8-regulated molecular cascades play important roles during thyroid tumorigenesis PMID: 27249794
10. Putative PAX8 target genes are enriched for common serous epithelial ovarian cancer risk variants. PMID: 28103614
11. We conclude that PAX8 immunostain is negative in most cervical cell carcinomas and is less frequently expressed in endocervical adenocarcinomas as compared with the previously reported high sensitivity for ovarian and endometrial adenocarcinomas PMID: 27362905
12. Study postulated that both TTF-1 and PAX-8 when co-expressed and have anti-proliferative and anti-tumorigenic properties up to a threshold expression level and beyond that, are able to induce pro-tumorigenic effects in thyroid carcinomas. PMID: 27573549
13. Direct sequencing of the PAX8 gene revealed a novel single nucleotide substitution (c.162 A>T) in exon 2 that resulted in the substitution of the normal serine 54 with a cysteine (S54C), which segregated with elevated serum TSH levels. PMID: 27207603
14. This is the first report of PAX8 aberrant transcript production in cervical cancer. Reported PAX8 isoforms possess differential transactivation properties; therefore, besides being a helpful marker for detection of cancer, PAX8 isoforms can plausibly exert differential regulation properties during carcinogenesis PMID: 27175788
15. PAX2, PAX8, CDX2 immunostains was preformed to the TMA slides. PMID: 26797858
16. Pax8 gene Rearrangement is associated with Breast Cancer. PMID: 27797226
17. PAX8 was negative in all cases of pulmonary neuroendocrine carcinoma (PNEC) while positive in 86.4% of thymic cases (TNEC). TTF-1 positivity was associated with high sensitivity but low specificity for PNEC, and adding PAX8 negativity significantly increased the specificity. PAX8 positivity alone showed essentially 100% specificity and 86.4% sensitivity for TNEC. PMID: 27761900
18. Study suggested that PAX8 eQTLs SNPs (rs4848320 and rs1110839) located in lncRNA PAX8-AS1 might predict decreased risk of cervical cancer. PMID: 27225188
19. High Levels of mRNA of both PAX8 are associated with benign than in malignant thyroid lesions. PMID: 26370671
20. results indicate that presence of PAX8 immunoreactivity in an undifferentiated brain tumor lacking gliofibrillary acidic protein expression should prompt consideration of a metastatic tumor PMID: 26371431
21. rete ovarii were positive for PAX-8, weakly positive for SF-1, and negative for PAX-2 and GATA-3 PMID: 26352548
22. showing that the PAX8 mutation rate is very low in thyroid dysgenesis patients in China PMID: 26617871
23. a substantial minority of solitary fibrous tumors express nuclear PAX8 and PAX2 PMID: 26404914
24. PAX8 staining is useful for distinguishing between primary thyroid squamous cell carcinoma and invasion or metastasis from extrathyroidal squamous cell carcinoma. PMID: 26354716
25. PAX8 is expressed in the majority of benign, premalignant, and malignant endocervical glandular lesions. PMID: 26910219
26. PAX8 mutation rate among congenital hypothyroidism patients PMID: 26362610
27. the novel interplay between PAX8 and Neuropilin-2 PMID: 26030152
28. Heterozygous transition in exon 3 of PAX8 gene is associated with hyroid hypoplasia. PMID: 25720050
29. miR-146b-3p binds to the 3'-untranslated region of PAX8 and sodium/iodide symporter. miR-146b and PAX8 regulate each other and share common target genes. PMID: 26282166
30. we examined PAX8-PPARgamma rearrangement in 24 follicular thyroid carcinoma samples from Japanese patients. The fusion gene was detected in only one of 24 follicular thyroid carcinomas (4%). PMID: 25708358
31. PAX8 protein expression was associated with germinal layers in forebrain and hindbrain development...and PAX8 expression is linked to better prognosis in medulloblastomas PMID: 25287489
32. PAX2 and PAX8 are useful biomarker in the differential diagnosis of ovarian serous and mucinous tumors PMID: 24992169
33. immunohistochemical marker, which allows to differentiate seminal vesicle from prostate gland epithelium in prostate needle biopsies PMID: 25153494
34. PAX6 and PAX8 positivity was seen in of metastatic pancreatic neuroendocrine tumors to the liver PMID: 25433656
35. In this series, PAX8/PPARgamma rearrangement found in thyroid nodules had a 100% predictive value for differentiated thyroid cancer PMID: 24798894
36. Compared with RAS or PAX8/PPARG-positive TCs, BRAFV600E or RET/PTC-positive Thyroid cancers were more often associated with stage III/IV disease and recurrence. PMID: 26258321
37. PAX8 (mAb) was a specific marker in differentiating primary and extragenital metastatic mucinous ovarian tumours. PMID: 25827135
38. PAX8 is frequently expressed by ovarian surface epithelial cells, and endogenous levels of PAX8 expression are non-transforming. PMID: 26079312
39. Case Report: novel PAX8 mutation is responsible for a severe form of dominantly inherited congenital hypothyroidism. The mutation seems to be associated with abnormalities of the urogenital tract. PMID: 23647375
40. PAX8 immunoexpression was noticed in five and three cases of alveolar rhabdomyosarcomas and embryonal rhabdomyosarcomas, respectively. About one-third of malignant rhabdoid tumors were PAX2-positive and PAX8-positive. PMID: 24897005
41. PAX8 is expressed in the vast majority of uterine adenocarcinomas, and that the level of expression based on combined extent and intensity is highest in endometrial serous carcinoma and lowest in endocervical adenocarcinoma. PMID: 25083965
42. useful in distinguishing thymic carcinoma from poorly differentiated lung carcinoma PMID: 23958552
43. We reviewed the reliability of PAX8 to determine tumor type or primary site in 135 current clinical pelvic or abdominal lesions PMID: 24857336
44. The 5'-flanking region of the Wnt4 gene is responsive to Pax8. Pax8 modulates the expression of Wnt4 in thyroid cells. PMID: 25270402
45. our results indicate that PAX8 plays an important role in the tumorigenic phenotype of ovarian cancer cells and identifies PAX8 as a potential new target for the treatment of ovarian cancer. PMID: 24766781
46. PAX8 is expressed in the carcinomatous components of nearly all uterine malignant mesodermal mixed tumors, with expression in sarcomatous and undifferentiated components being less common and less extensive. PMID: 24901404
47. This study confirms that PAX-8 expression is a useful diagnostic marker for renal cell carcinoma PMID: 25315900
48. PAX8 is increased in the majority of glioblastomas and promoted cell survival. PMID: 24602166
49. R133W-PAX8 variant is associated with phenotype ranging from congenital hypothyroidism with thyroid hypoplasia to mild subclinical hypothyroidism. PMID: 25146893
50. Data shows that PAX8 provides signals for growth and motility of non-small cell lung cancer cells and is necessary for MET and RON expression. PMID: 24628993
顯示更多

收起更多
相關(guān)疾病：

Hypothyroidism, congenital, non-goitrous, 2 (CHNG2)
亞細(xì)胞定位：

Nucleus.
組織特異性：

Expressed in the excretory system, thyroid gland and Wilms tumors.
數(shù)據(jù)庫鏈接：

HGNC: 8622

OMIM: 167415

KEGG: hsa:7849

STRING: 9606.ENSP00000395498

UniGene: Hs.469728

Most popular with customers

YWHAG Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
YWHAB Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF, FC

Species Reactivity: Human, Mouse, Rat
Phospho-YAP1 (S127) Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
XRCC5 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC, IF

Species Reactivity: Human
XDH Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WT1 Recombinant Monoclonal Antibody

Applications: ELISA, WB, IHC

Species Reactivity: Human
WFDC2 Recombinant Monoclonal Antibody

Applications: ELISA, WB, FC

Species Reactivity: Human
WDR5 Recombinant Monoclonal Antibody

Applications: ELISA, IHC, FC

Species Reactivity: Human